Sun Pharma receives USFDA nod for anti-cholesterol drug
- TCS 1st Indian company to close trading session with $100 billion market cap
- Axis Bank posts Q4 loss of Rs2,189 crore on provisions for bad loans
- India will network with Asia’s major oil buyers to bargain with sellers
- Lodha Developers files IPO paper with Sebi
- Dish TV’s Rs3,701 crore open offer to start on 5 June
New Delhi: Drug major Sun Pharmaceutical Industries’ wholly-owned subsidiary has received nod from the US health regulator for its generic version of ezetimibe tablets used to reduce high cholesterol levels.
One of the company’s wholly-owned subsidiaries has received final approval from the USFDA for its abbreviated new drug application (ANDA) for generic version of Zetia, ezetimibe tablets, Sun Pharma said in a BSE filing.
The approval is for the tablets in the strength of 10 mg. The tablets are generic versions of Merck’s Zetia, Sun Pharma said.
“As per IMS, ezetimibe tablets had annual sales of approximately $2.7 billion in the US for the 12 months ended April 2017,” it added.
The stock of Sun Pharmaceutical Industries was trading at Rs539.50 on the BSE, up 1.19%.